Gillis C, Bengtsson L, Wilman B, Haegerstrand A
Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.
Eur J Vasc Endovasc Surg. 1996 Feb;11(2):127-33. doi: 10.1016/s1078-5884(96)80040-2.
The aim of this study was to investigate the secretion of prostacyclin (PGI2), tissue plasminogen activator (tPA) and plasminogen activator inhibitor type 1 (PAI- 1) produced by human great saphenous vein endothelial cells (HSVECs) in vitro when seeded to confluency on different matrices.
The matrices compared were: uncoated plastic, gelatin, collagen type-I gel, fibronectin, fibrin glue, de-endothelialized porcine aorta and ePTFE vascular grafts pre-coated with collagen type-I or human serum.
There were no significant differences between basal production of PGI2 on the different matrices. The HSVECs responded with a significant increase in PGI2 secretion after stimulation with thrombin on all matrices, including the ePTFE grafts. A statistically significant higher secretion of tPA secretion was found in supernatants from cells cultured on collagen type-I gel. Interestingly, tPA secretion was lower by cells seeded on both collagen type-I and serum precoated ePTFE as compared to collagen type-1 gel. PAI-1 secretion however was significantly higher on collagen type-1 gel, gelatin, fibrin glue and porcine aorta but not on pre-coated ePTFE grafts.
The findings emphasise the important effect of the matrix on endothelial secretion of PGI2, tPA and PAI-1. Differences in patency after implantation of in vitro endothelialized grafts, may be due to cellular function depending on the types of graft and matrix chosen.
本研究旨在调查人大隐静脉内皮细胞（HSVECs）在体外接种于不同基质达到汇合状态时，前列环素（PGI2）、组织型纤溶酶原激活剂（tPA）和纤溶酶原激活剂抑制剂1型（PAI-1）的分泌情况。
所比较的基质有：未包被的塑料、明胶、I型胶原凝胶、纤连蛋白、纤维蛋白胶、去内皮猪主动脉以及预包被I型胶原或人血清的ePTFE血管移植物。
不同基质上PGI2的基础分泌量之间无显著差异。在所有基质（包括ePTFE移植物）上，用凝血酶刺激后，HSVECs的PGI2分泌均显著增加。在I型胶原凝胶上培养的细胞上清液中，tPA分泌量在统计学上显著更高。有趣的是，与I型胶原凝胶相比，接种在I型胶原和血清预包被的ePTFE上的细胞tPA分泌较低。然而，PAI-1分泌在I型胶原凝胶、明胶、纤维蛋白胶和猪主动脉上显著更高，但在预包被的ePTFE移植物上则不然。
这些发现强调了基质对内皮细胞分泌PGI2、tPA和PAI-1的重要影响。体外内皮化移植物植入后通畅率的差异，可能归因于取决于所选择的移植物和基质类型的细胞功能。
